Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …

The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging …

Radiotheranostics refers to the pairing of radioactive imaging biomarkers with radioactive
therapeutic compounds that deliver ionizing radiation. Given the introduction of very …

Reliable biomarkers for neuroendocrine tumor (NET) management during peptide receptor
radionuclide therapy (PRRT) are lacking. We validated the role of 2 circulating biomarkers …

Abstract Background Somatostatin receptor 68Ga PET imaging is standard for evaluation of
a patient's suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine …

Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has
been used for over two decades for the treatment of well-differentiated neuroendocrine …

Background Peptide receptor radionuclide therapy (PRRT) is one of the most effective
therapeutic options for the treatment of metastatic, well-differentiated neuroendocrine tumors …

Simple Summary The monitoring of disease in patients with neuroendocrine tumors is
challenging and requires specialized imaging techniques. To address these quests …

Simple Summary Although a significant improvement has been achieved in the
management of metastatic neuroendocrine tumor (NET), disease progression is observed in …

Neuroendocrine tumors (NETs) are uncommon malignancies of increasing incidence and
prevalence. As these slow growing tumors usually overexpress somatostatin receptors …